The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study
Open Access
- 7 August 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Psychiatry
- Vol. 19 (1), 1-11
- https://doi.org/10.1186/s12888-019-2222-4
Abstract
A patient is considered to suffer from treatment resistant depression (TRD) when consecutive treatment with two products of different pharmacological classes, used for a sufficient length of time at an adequate dose, fail to induce a clinically meaningful effect (inadequate response). The primary aim of the current study was to examine the humanistic and economic burden of TRD in five European countries, France, Germany, Italy, Spain and the United Kingdom, by comparing with non-treatment resistant depression (nTRD) and general population respondents. The sample for this retrospective observational study was taken from the 2017 National Health and Wellness Survey conducted in five European countries. Demographic and patient characteristics were examined for TRD patients compared to respondents with nTRD and to the general population using chi-square tests or one-way analysis of variance for categorical or continuous variables, respectively. Generalized linear models were performed to examine group differences after adjusting these estimates for confounders. A total 52,060 survey respondents were examined, of which 2686 and 622 were considered to have non-treatment resistant and treatment-resistant depression, respectively. Relative to the general population, nTRD and TRD respondents reported significant decrements in health-related quality of life, including lower adjusted mental (− 12.1 vs. -18.1) and physical (− 2.5 vs. -5.4) component scores of the SF-12v2 and increased adjusted relative risk for work (2.2 vs. 2.7) and activity (1.9 vs. 2.5) impairment (all p < 0.001). Additionally, healthcare resource utilization was significantly higher for TRD patients more so than nTRD, compared to the general population, especially for healthcare professional visits (odds ratio nTRD = 5.4; TRD = 15.9, p < 0.001). In conclusion, TRD patients had significantly lower quality of life, greater work productivity and activity impairment, and increased healthcare resource utilization as compared with nTRD and general population. The study findings suggest an unmet need exists among TRD patients in Europe.Keywords
Funding Information
- Janssen Pharmaceuticals
This publication has 39 references indexed in Scilit:
- Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims DatabasePLOS ONE, 2013
- Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in BrazilValue in Health Regional Issues, 2012
- Treatment-resistant depression: therapeutic trends, challenges, and future directionsPatient Preference and Adherence, 2012
- The size and burden of mental disorders and other disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The European Study of the Epidemiology of Mental Disorders (ESEMeD) project: an epidemiological basis for informing mental health policies in EuropeActa Psychiatrica Scandinavica, 2004
- Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) projectActa Psychiatrica Scandinavica, 2004
- The Mood Disorder QuestionnaireThe Primary Care Companion For CNS Disorders, 2002
- The PHQ-9Journal of General Internal Medicine, 2001
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993